Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.65B 4.04B 3.76B 3.46B 6.54B 442B 6.61B 44.37B 17.35B 221B 17.46B 17.08B 732B P/E 2026 *
58.4x
P/E 2027 * 34.8x
Enterprise Value 3.68B 3.19B 2.98B 2.74B 5.17B 350B 5.23B 35.12B 13.73B 175B 13.82B 13.51B 580B EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.45x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+5.19%
1 week+7.19%
Current month+9.14%
1 month+9.57%
3 months+26.33%
6 months+20.35%
Current year+5.71%
1 week 25.34
Extreme 25.345
29.16
1 month 24.23
Extreme 24.232
29.16
Current year 19.89
Extreme 19.89
29.16
1 year 19.69
Extreme 19.69
29.16
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
30/07/26 Sell

Chief Technology Officer

-16,558 0.0097%
06/02/26 Fiscal year

General Counsel

32,838 0.0194%
17/11/25 Fiscal year

Controller/Auditor

19,948 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
+6.08%+7.19%+19.44%+5.35% 4.65B
+0.36%-2.85%+0.14%+13.91% 48B
+0.60%+7.20%+405.22%+554.37% 41.13B
+2.84%-4.79%+28.15%+7.48% 37.56B
+1.92%+0.78%+7.34%+75.86% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.31%-2.71% - - 16.12B
+1.33%+0.12%+34.22%+124.90% 16.05B
+1.31%+1.69%+4.80%+18.87% 13.76B
+4.50%-7.89%-1.12%-34.76% 12.1B
Average +2.36%-1.49%+57.01%+90.09% 25.51B
Weighted average by Cap. +1.91%-1.19%+80.04%+124.17%

Financials

2026 *2027 *
Net sales 1.25B 1.09B 1.01B 931M 1.76B 119B 1.78B 11.95B 4.67B 59.52B 4.7B 4.6B 197B 1.42B 1.23B 1.15B 1.05B 1.99B 135B 2.01B 13.51B 5.28B 67.29B 5.31B 5.2B 223B
Net income 80.26M 69.69M 64.98M 59.69M 113M 7.63B 114M 766M 299M 3.82B 301M 295M 12.65B 143M 125M 116M 107M 202M 13.64B 204M 1.37B 535M 6.82B 538M 527M 22.59B
Net Debt -970M -842M -785M -721M -1.36B -92.26B -1.38B -9.26B -3.62B -46.12B -3.64B -3.56B -153B -1.18B -1.03B -958M -880M -1.66B -113B -1.68B -11.29B -4.41B -56.26B -4.44B -4.35B -186B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
05/08/26 US$28.72 +5.78% 2,030,959
04/08/26 US$27.15 +6.01% 2,440,393
03/08/26 US$25.61 -1.01% 1,368,071
31/07/26 US$25.87 -2.56% 1,534,224
30/07/26 US$26.55 +0.80% 1,298,677
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
27.15USD
Average target price
33.00USD
Spread / Average Target
+21.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock